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Abstract We report a case of an allergic reaction after the
administration of an echocardiographic contrast agent
which resulted in ST-segment elevation. Hypersensitivity
and allergic reactions are known causes of acute cardio-
vascular events. However, only limited reports are avail-
able which suggest the exact mechanism of the occurrence
of angina or myocardial infarction during severe allergic
reactions. In our case, through invasive imaging (coronary
angiography and IVUS) we have shown for the first time
a transient coronary spasm in the absence of intra-coro-
nary thrombus and only minimal neointimal hyperplasia.
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Introduction
Contrast echocardiography for opacification of the left
ventricle is widely used to enhance diagnostic accuracy
of conventional two-dimensional or three-dimensional
stress echocardiography [1, 2]. SonoVue® (BraccoSPA,
Milan, Italy) is a second-generation ultrasound contrast
agent that is made of stabilised microbubbles containing
sulphur-hexafluoride, for which an incidence of allergic
reactions of approximately 2 % has been reported, includ-
ing anaphylactic shock [3]. We describe a rare complica-
tion following SonoVue® administration.
Case
A 60-year-old man was referred for contrast-enhanced
dobutamine stress echocardiography (DSE) for detection of
ischaemia. Two years before, the patient had an inferolateral
myocardial infarction treated with a primary percutaneous
coronary intervention and implantation of a drug-eluting
stent in the right coronary artery (RCA). A few months
before DSE, he complained of recurrence of typical angina
pectoris due to a stenosis proximal to the stented segment in
the RCA, which was successfully treated with implantation
of a second drug-eluting stent (Fig.1a). However, few weeks
later, he developed new atypical thoracic symptoms, for
which he was referred for DSE[4].
At the beginning of the procedure, the patient’s blood
pressure was 135/75 mmHg, his heart rate was 79 beats/min
and ECG showed sinus rhythm and right bundle-branch
block (Fig.1a). Before starting the infusion of dobutamine,
SonoVue® was administered to optimise visualisation of the
left ventricle. One minute after administration of a 1 ml bolus
of SonoVue®, the patient started complaining of nausea with
profuse sweating and hypotension (100/45 mmHg). These
signs were treated as an allergic reaction with clemastine
(2 mg), hydrocortisone (100 mg), oxygen and saline infu-
sion. Two minutes later, sudden severe chest pain occurred
and the ECG showed ST-segment elevation in leads II, III,
aVF and V2-V4, with ST-segment depression in V2-V4, I,
and aVL, and total AV-nodal block (Fig.1b). During this
episode, echocardiography showed akinesia of the inferior
wall, whereas baseline echocardiography showed only mild
mid-inferior hypokinesia. After 8 min (as measured on the
monitor), the symptoms started to decrease and the ST seg-
ments normalised (Fig.1b). Immediate coronary angiography
was performed showing a good patency of the stents in the
RCA. However, a 50% stenosis was observed proximally to the
stented segment, which was interpreted as a possible coronary
spasm (Fig.1b). No significant pathology was observed in the
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left coronary artery. Intravascular ultrasonography of the RCA
was also performed and showed minimal neo-intimal hyperpla-
sia (Fig.1b) with no significant stenosis. Further angiographic
projections confirmed complete resolution of the spasm
(Fig.1b). The patient was admitted to the coronary care unit
and observed for 12 h. His recovery was uneventful and tropo-
nin T remained within normal ranges (0.016 μg/l).
Discussion
Hypersensitivity and allergic reactions are well-known causes
of acute cardiovascular events. In 1991 a syndrome including
angina pectoris together with the occurrence of an allergic
reaction was described and called Kounis syndrome[5]. The
Type I variant of this syndrome includes patients with normal
coronary arteries. Type II includes patients with significant but
quiescent atherosclerotic disease[6]. In both cases, activation of
the mast cells leads to the release of several compounds,
including histamine, platelet-activating factor and cytokines,
which have been shown to induce coronary artery spasm and/or
acute myocardial infarction in several clinical and experimental
studies [7].
In this case administration of the echo contrast caused the
Kounis syndrome.
Endocardial visualisation with contrast echocardiography is
widely used to improve the diagnostic accuracy of DSE [1, 2].
In particular, SonoVue® was introduced in 2001 and is current-
ly the only echo contrast agent used in European countries.
After its introduction, the European Medicines Agency (EMA)
received several alerts of allergic reactions with secondary
cardiovascular problems[8]. After these reports, in 2004, the
Fig. 1 Panel a: ECG (left panel, showing RBBB) and coronary angi-
ography (right panel, showing the result of the implantation of two drug-
eluting stents in the RCA and normal LAD) of the patient before DSE.
Panel b: ECG of the patient during the allergic reaction to SonoVue®
(left, upper panel) and after resolution of the symptoms (left, lower
panel). Coronary angiography of the RCA shortly after the beginning
of the allergic reaction to SonoVue® (middle, upper panel, showing 50%
proximal stenosis due to coronary spasm) and few minutes later after
resolution of the symptoms (middle, lower panel, showing resolution of
the coronary spasm). IVUS of the RCA (right panel, with longitudinal
and cross-sectional views) showing the presence of two drug-eluting
stents with minimal neointimal hyperplasia with no significant lumen
reduction. RBBB=right bundle branch block, RCA=right coronary ar-
tery, LAD=left anterior descending coronary artery, DSE=dobutamine
stress echocardiography, IVUS=intravascular ultrasonography
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EMA took precautionary measures to limit the use of
SonoVue® in patients with unstable cardiac conditions[9]. A
post-marketing analysis of the manufacturer of SonoVue® in-
volving 157,838 patients showed 0.01 % nonfatal severe and
0.02 % fatal complications. In 2006, a safety study of contrast
DSE was performed and showed that among 419 patients
receiving SonoVue® or Optison®, an overall 4 % experienced
side effects, with no deaths or myocardial infarctions[10].
Geleijnse et al. systematically reviewed all adverse events
reported in patients receiving SonoVue® during DSE in their
centre[11]: 1.1 % had mild allergic reactions and 0.9 % expe-
rienced a severe allergic reaction resulting in (nonfatal) shock.
However, a severe anaphylactic reaction with reversible ST-
segment elevation was reported by Calco et al. when SonoVue®
was administered at a peak dose in DSE[12]. In another case
report, reversible ST-segment elevation was reported after ad-
ministration of Sonovue® but before startingDSE[13]. However,
coronary angiography was not performed in either of these
patients, while the current case report could demonstrate the
absence of intra-coronary thrombus, but the presence of signifi-
cant coronary spasm as a cause of the ST-segment elevation [14].
In conclusion, SonoVue®, which is often indispensable to
improve the diagnostic accuracy of DSE, is a safe pharmaco-
logical agent, for which adverse events are rare and usually of
minor consequences. However, a few cases of life-threatening
allergic reaction have been described, making it essential that
its use is restricted to a safe environment, under monitoring of
vital signs and with availability of full resuscitation facilities.
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